Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases-Reference-Cited by-同舟云学术

Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases

Published:2022-12-08 Issue:3 Volume:58 Page:340-342
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Otiniano Armelle,van de Wyngaert Zoe,Brissot Eolia^ORCID,Dulery Rémy^ORCID,Gozlan Joel,Daguenel Anne,Abi Aad Yasmine,Ricard Laure,Stocker Nicolas^ORCID,Banet Anne,Bonnin Agnes,Alsuliman Tamim,Marjanovic Zora,Schnuriger Aurélie,Coppo Paul,Legrand Ollivier,Lacombe Karine,Mohty Mohamad^ORCID,Malard Florent^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-022-01894-1.pdf

Reference10 articles.

1. Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–92. https://doi.org/10.1182/blood.2020008824.

2. Dejnirattisai W, Huo J, Zhou D, Zahradník J, Supasa P, Liu C, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185:467–484.e415. https://doi.org/10.1016/j.cell.2021.12.046.

3. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399:1303–12. https://doi.org/10.1016/s0140-6736(22)00462-7.

4. Blennow O, Salmanton-García J, Nowak P, Itri F, Van Doesum J, López-García A, et al. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report. Am J Hematol. 2022;97:E312–e317. https://doi.org/10.1002/ajh.26626.

5. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. Lancet Respir Med. 2022. https://doi.org/10.1016/s2213-2600(22)00215-6.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients—A Tailored Approach Based on SARS-CoV-2 Vaccine Response;Vaccines;2024-08-01

2. Efficacy of Preexposure Prophylaxis with Monoclonal Antibody Tixagevimab-Cilgavimab against Emerging SARS-CoV-2 Resistant Variants in Patients with Chronic Lymphocytic Leukemia;Acta Haematologica;2024-03-12

3. COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches;Cell Communication and Signaling;2024-02-15

4. Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era;Diseases;2023-09-18

5. SARS-CoV-2 infection in high-risk children following tixagevimab–cilgavimab (Evusheld) pre-exposure prophylaxis: a single-center observational study;Frontiers in Oncology;2023-08-03